Delivery Order SPE2DB24D2101-SPE2DB25FKFJN
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,563.78 firm fixed-price delivery order is for the supply of the specialty drug ONIVYDE 43 MG/10 ML VIAL 10ML. The contract has an ultimate completion date of March 31, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive...
- This federal contract award, valued at $6,741.60, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ONIVYDE 43 MG/10 ML VIAL 10ML, with a completion date of November 13, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ONIVYDE 43 MG/10 ML VIAL 10ML. The contract is a Firm Fixed Price Delivery Order valued at $8,718.25 with an ultimate completion date of December 23, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves...
- This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,112.40, is for the delivery of ONIVYDE 43 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of November 21, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,461.90 delivery order contract is for the supply of ONIVYDE 43 MG/10 ML VIAL 10ML, a specialty medication. The contract has a firm fixed price pricing type and a completion date of January 9, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of ONIVYDE 43 MG/10 ML VIAL 10ML. The contract has a ceiling value of $10,691.34 and an ultimate completion date of August 6, 2025. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX,...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ONIVYDE 43 MG/10 ML VIAL 10ML, a pharmaceutical product, with a ceiling value of $5,345.67 and a performance period through June 3, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $15,168.60 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of ONIVYDE 43 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,178.78, is a delivery order for the pharmaceutical product "ONYDA XR 0.1 MG/ML SUSPENSION 60ML". The contract has an ultimate completion date of January 6, 2025 and is a firm fixed-price contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award is for the delivery of OPDIVO 240 MG/24 ML VIAL 24ML pharmaceutical products to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The $30,197.82 delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on May 19, 2025, with a completion date of June 10, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. Amerisourcebergen Drug...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKFJNDelivery Order
This federal contract award is for the pharmaceutical product ONIVYDE 43 MG/10 ML VIAL 10ML, with a ceiling value of $5,056.20. The contract was awarded by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of December 4, 2024 and is structured as a Firm Fixed Price Delivery Order. The award does not indicate any set-aside requirements, suggesting open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 11/12/24 |